Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

Bone

Volumn 45, Issue 6, 2009, Pages 1053-1058

  Glover, Sarah J ^a   Eastell, Richard ^a   McCloskey, Eugene V ^a   Rogers, Angela ^a   Garnero, Patrick ^b   Lowery, Jonathan ^c   Belleli, Rossella ^c   Wright, Timothy M ^c   John, Markus R ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b INSERM   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone turnover markers; PINP; Postmenopausal osteoporosis; S CTX; Teriparatide

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN TYPE 1 AMINOPROPEPTIDE; COLLAGEN TYPE 1 CARBOXYPROPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CONFIDENCE INTERVALS; FEMALE; HUMANS; MIDDLE AGED; OSTEOGENESIS; TERIPARATIDE;

EID: 70350230386     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.07.091     Document Type: Article

References (21)

1. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20 (2005) 1244-1253
2. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
3. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18 (2003) 1932-1941
4. Graeff C., Timm W., Nickelsen T.N., Farrerons J., Marin F., Barker C., et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J. Bone Miner. Res. 22 (2007) 1426-1433
5. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350 (1997) 550-555
6. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., and Steer B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 91 (1993) 1138-1148
7. Bauer D.C., Garnero P., Bilezikian J.P., Greenspan S.L., Ensrud K.E., Rosen C.J., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 91 (2006) 1370-1375
8. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970
9. Bilezikian J.P. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr. Osteoporos. Rep. 6 (2008) 24-30
10. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 90 (2005) 3970-3977
11. Anastasilakis A.D., Goulis D.G., Polyzos S.A., Gerou S., Koukoulis G.N., Efstathiadou Z., et al. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int. J. Clin. Pract. 62 (2008) 919-924
12. Plotkin H., Gundberg C., Mitnick M., and Stewart A.F. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab. 83 (1998) 2786-2791
13. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone. Miner. Res. 21 (2006) 366-373
14. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., and Hodsman A.B. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone. Miner. Res. 22 (2007) 495-502
15. Dempster D.W., Hughes-Begos C.E., Plavetic-Chee K., Brandao-Burch A., Cosman F., Nieves J., et al. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J. Cell. Biochem. 95 (2005) 139-148
16. Anastasilakis A.D., Goulis D.G., Polyzos S.A., Gerou S., Koukoulis G., Kita M., et al. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm. Metab. Res. 40 (2008) 281-285
17. Ohlsson C., Nilsson A., Isaksson O., and Lindahl A. Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9826-9830
18. Canalis E., Centrella M., Burch W., and McCarthy T.L. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83 (1989) 60-65
19. Ghiron L.J., Thompson J.L., Holloway L., Hintz R.L., Butterfield G.E., Hoffman A.R., et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J. Bone. Miner. Res. 10 (1995) 1844-1852
20. Yakar S., and Rosen C.J. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp. Biol. Med. (Maywood. ). 228 (2003) 245-252
21. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319